Literature DB >> 16940121

In vitro activities of DA-7157 and DA-7218 against Mycobacterium tuberculosis and Nocardia brasiliensis.

Lucio Vera-Cabrera1, Eva Gonzalez, Adrian Rendon, Jorge Ocampo-Candiani, Oliverio Welsh, Victor M Velazquez-Moreno, Sung Hak Choi, Carmen Molina-Torres.   

Abstract

The in vitro activities of DA-7157, a novel oxazolidinone, against clinical isolates of Nocardia brasiliensis and Mycobacterium tuberculosis were determined. Equal MIC(50)s and MIC(90)s (0.25 and 0.5 microg/ml, respectively) were found for susceptible and multidrug-resistant isolates of M. tuberculosis. The N. brasiliensis isolates showed an MIC(90) of 1 microg/ml and an MIC(50) of 1 microg/ml. The DA-7157 prodrug, DA-7218, exhibited similar MICs for M. tuberculosis but fivefold-higher MICs for N. brasiliensis.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16940121      PMCID： PMC1563545          DOI： 10.1128/AAC.00571-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  In vitro susceptibility of Mycobacterium tuberculosis clinical isolates to garenoxacin and DA-7867.

Authors:  Lucio Vera-Cabrera; Jorge Castro-Garza; Adrian Rendon; Jorge Ocampo-Candiani; Oliverio Welsh; Sung Hak Choi; Kym Blackwood; Carmen Molina-Torres
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

2.  Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations.

Authors:  Ronald N Jones; James E Ross; Thomas R Fritsche; Helio S Sader
Journal:  J Antimicrob Chemother       Date:  2005-12-02       Impact factor: 5.790

3.  Mechanism of action of the oxazolidinone antibacterial agents.

Authors:  D Shinabarger
Journal:  Expert Opin Investig Drugs       Date:  1999-08       Impact factor: 6.206

4.  Linezolid for the treatment of multidrug-resistant tuberculosis.

Authors:  Jesús Fortún; Pilar Martín-Dávila; Enrique Navas; Ma Jesús Pérez-Elías; Javier Cobo; Marta Tato; Elia Gómez-G De la Pedrosa; Enrique Gómez-Mampaso; Santiago Moreno
Journal:  J Antimicrob Chemother       Date:  2005-05-23       Impact factor: 5.790

5.  Clinical experience with linezolid for the treatment of nocardia infection.

Authors:  Edina H Moylett; Susan E Pacheco; Barbara A Brown-Elliott; Tracy R Perry; E Stephen Buescher; Mary C Birmingham; Jerome J Schentag; Joseph F Gimbel; Aaron Apodaca; Margot A Schwartz; Robert M Rakita; Richard J Wallace
Journal:  Clin Infect Dis       Date:  2003-01-13       Impact factor: 9.079

6.  [Epidemiology of mycetoma in Mexico: study of 2105 cases].

Authors:  R López Martínez; L J Méndez Tovar; P Lavalle; O Welsh; A Saúl; E Macotela Ruíz
Journal:  Gac Med Mex       Date:  1992 Jul-Aug       Impact factor: 0.302

7.  In vitro activities of new antimicrobials against Nocardia brasiliensis.

Authors:  Lucio Vera-Cabrera; Eva Gonzalez; Sung H Choi; Oliverio Welsh
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

8.  In vitro and in vivo activities of antimicrobials against Nocardia brasiliensis.

Authors:  Alejandra Gomez-Flores; Oliverio Welsh; Salvador Said-Fernández; Gerardo Lozano-Garza; Roman Erick Tavarez-Alejandro; Lucio Vera-Cabrera
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

9.  In vitro activities of new quinolones and oxazolidinones against Actinomadura madurae.

Authors:  Lucio Vera-Cabrera; Elsa Y Ochoa-Felix; Gloria Gonzalez; Rolando Tijerina; Sung H Choi; Oliverio Welsh
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191
  9 in total
  25 in total

Review 1.  Signed, Sealed, Delivered: Conjugate and Prodrug Strategies as Targeted Delivery Vectors for Antibiotics.

Authors:  Ana V Cheng; William M Wuest
Journal:  ACS Infect Dis       Date:  2019-04-10       Impact factor: 5.084

2.  In Vitro Activity of Tedizolid against Mycobacterium tuberculosis.

Authors:  Pilar Ruiz; Manuel Causse; Manuel Vaquero; Manuel Casal
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

3.  In vitro activities of the novel oxazolidinones DA-7867 and DA-7157 against rapidly and slowly growing mycobacteria.

Authors:  Lucio Vera-Cabrera; Barbara A Brown-Elliott; Richard J Wallace; Jorge Ocampo-Candiani; Oliverio Welsh; Sung Hak Choi; Carmen A Molina-Torres
Journal:  Antimicrob Agents Chemother       Date:  2006-10-02       Impact factor: 5.191

Review 4.  The expanding role of prodrugs in contemporary drug design and development.

Authors:  Jarkko Rautio; Nicholas A Meanwell; Li Di; Michael J Hageman
Journal:  Nat Rev Drug Discov       Date:  2018-04-27       Impact factor: 84.694

5.  In Vitro Susceptibility Testing of Tedizolid against Nontuberculous Mycobacteria.

Authors:  Barbara A Brown-Elliott; Richard J Wallace
Journal:  J Clin Microbiol       Date:  2017-03-22       Impact factor: 5.948

6.  Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges.

Authors:  Steven D Brown; Maria M Traczewski
Journal:  Antimicrob Agents Chemother       Date:  2010-03-15       Impact factor: 5.191

7.  In Vitro Susceptibility Testing of Tedizolid against Isolates of Nocardia.

Authors:  Barbara A Brown-Elliott; Richard J Wallace
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

8.  Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis.

Authors:  Reynaldo Dietze; David Jamil Hadad; Bryan McGee; Lucilia Pereira Dutra Molino; Ethel Leonor Noia Maciel; Charles A Peloquin; Denise F Johnson; Sara M Debanne; Kathleen Eisenach; W Henry Boom; Moises Palaci; John L Johnson
Journal:  Am J Respir Crit Care Med       Date:  2008-09-11       Impact factor: 21.405

9.  In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains.

Authors:  K J Shaw; S Poppe; R Schaadt; V Brown-Driver; J Finn; C M Pillar; D Shinabarger; G Zurenko
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

10.  Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis.

Authors:  Rokeya Tasneen; Fabrice Betoudji; Sandeep Tyagi; Si-Yang Li; Kathy Williams; Paul J Converse; Véronique Dartois; Tian Yang; Carl M Mendel; Khisimuzi E Mdluli; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2015-10-26       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.